Settlement

Pfizer settles off-label Rapamune case for $35M

Pfizer settles off-label Rapamune case for $35M

By

The drugmaker will dole out $35 million in a deal with 41 state attorneys general after a New York County Supreme Court judge said Wyeth allegedly promoted the immuno-suppressive drug improperly.

Lidoderm reps inflated drug's uses

Lidoderm reps inflated drug's uses

By

Endo settled off-label charges for $192 million, resolving civil "whistleblower" suits filed by two sales reps and a physician.

Merck may be near NuvaRing settlement

The drugmaker may be able to settle around 3,800 cases for $100 million.

Louisiana chucks Risperdal settlement

An appeals court says J&J does not have to pay $257.7 million.

Lawsuits cause J&J to open its checkbook

The company is paying $2.5 billion over its DePuy hip replacements and $11 million in a lawsuit over its seizure drug Topamax.

Business briefs: Pfizer, GlaxoSmithKline, AstraZeneca, Mallinckrodt

Pfizer settles Rapamune lawsuits; Moody's downgrades GSK; Astrazeneca pursues anemia medication; Mallinckrodt drugs gets priority review

Business Briefs Merck, GSK, Novo, Walgreen, Epocrates, Doximity

HPV vaccine price cut; Merck files new allergy med with FDA; GSK pursues online transparency; Walgreens ready for greater nurse autonomy; Epocrates ranks high among docs with tablets.

Novartis sued for alleged speaker-program abuse

By

The Swiss drug maker is defending itself against two civil fraud lawsuits filed within a week of each other.

Court could punt "Pay for Delay" back to Congress

By

Eight members of the Supreme Court heard testimony in the case of FTC v. Actavis this morning, and the fate of so-called "pay for delay" settlements hangs in the balance.

Business briefs: Gilead, Shire, The Medicines Co., HHS

HHS wants input for its TXT4Tots childhood advice program, Gilead releases some Hep. C clinical trial data, and Shire settles with the DOJ over disputed marketing practices.

GSK's Connelly: We've changed our ways (and please don't imprison execs)

GSK's Connelly: We've changed our ways (and please don't imprison execs)

By

GlaxoSmithKline's Dierdre Connelly peeled back the curtain on the company's sales force incentives revamp in a speech to the Pharmaceutical Regulatory and Compliance Congress, and pleaded for recognition that the industry had cleaned up the sketchy practices of the Blockbuster Era.

For Forest, one Bystolic test down, six to go

By

Forest Labs may have settled a patent challenge from generics maker Hetero, but the drugmaker has yet to come to terms with six others.

J&J sales up, but earnings wiped out by settlements, product liability and recall costs

By

Days after a $158 million settlement of charges that its Janssen unit fraudulently marketed Risperdal in Texas, Johnson & Johnson forecast fourth-quarter net earnings of just $218 million due to settlement costs and the recall of its DePuy ASR artificial hip.

Merck wraps up Vioxx litigation with feds, states: $1b in fines, new CIA

Merck wraps up Vioxx litigation with feds, states: $1b in fines, new CIA

By

Seven years after the biggest drug safety scandal since thalidomide was found to cause birth defects, Merck and the Justice Department announced a nearly $1 billion settlement of litigation over Vioxx, the Cox-2 pain drug found to cause strokes and heart attacks.

GSK hopes $3-bil. off-label settlement will end legal woes

By

GlaxoSmithKline's deal to resolve multiple US investigations into its sales and marketing practices—one of the largest settlements by a pharma company—aims to patch up several long-running legal disputes.

GSK values drive flips rep bonus incentives

GSK values drive flips rep bonus incentives

By

The drug industry must move from a mindset that emphasizes compliance with regulations to one steeped in core values of integrity and transparency if it is to regain the public's trust, GSK's Dierdre Connelly said at a conference yesterday.

Company news: GlaxoSmithKline

GlaxoSmithKline said it will take a fourth-quarter legal charge of about $3.5 billion to cover the cost of a government investigation into its sales and marketing practices, as well as future product-liability cases related to diabetes drug Avandia.

Ruling in FTC-Watson case may sway pay-for-delay debate in Senate

Ruling in FTC-Watson case may sway pay-for-delay debate in Senate

By

A US magistrate judge ruled that the Federal Trade Commission overstepped its authority when the agency tried to pressure a generic drug company to enter into a business deal with a competitor.

AstraZeneca settles Seroquel off-label suit for $520m, CIA

AstraZeneca settles Seroquel off-label suit for $520m, CIA

By

AstraZeneca agreed to pay $520 million and enter a five-year Corporate Integrity Agreement to settle a federal case against the company for off-label marketing of Seroquel, the Departments of Justice and Health and Human Services' Healthcare Enforcement Action Team announced.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters